Quantitation of blood plasma DNA as an index of in vivo cytotoxicity

Bret, L.; Lulé, Jacqueline; Alary, Cécile; Appolinaire-Pilipenko, Sylvie; Pourrat, Jacques; Fournié, Gilbert J.

doi:10.1016/0300-483x(90)90178-j

Cited by 14 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In nonpregnant individuals, the most likely mechanism leading to the release of cfDNA into their circulation is apoptosis or some other form of cell death and the concentration of circulating cfDNA is increased in patients with malignant disorders or injuries [30,31,32,33]. If in pregnancy cell death is also the mechanism governing the concentration of plasma maternal cfDNA, our findings suggest that the fetoplacental unit, by some hitherto unknown mechanisms, influences such maternal apoptosis.…”

Section: Discussionmentioning

confidence: 83%

Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes

Poon

Musci²,

Song³

et al. 2013

Fetal Diagn Ther

198

101

View full text Add to dashboard Cite

Objective: To examine the possible relationship between maternal and fetal characteristics and pregnancy outcomes on fetal and maternal cell-free (cf) DNA in maternal plasma at 11-13 weeks' gestation. Methods: cfDNA was extracted from maternal plasma of 1,949 singleton pregnancies and chromosome-selective sequencing was used to determine the proportion of cfDNA and total cfDNA counts which was of fetal and maternal origin. Multivariate regression analysis was used to determine whether specific maternal and fetal characteristics and pregnancy complications, such as preeclampsia (PE), early spontaneous preterm birth (SPB) and delivery of small for gestational age (SGA) neonates, were significant predictors of fetal and maternal cfDNA in maternal plasma. Results: The fetal and maternal cfDNA plasma concentration increased with serum pregnancy-associated plasma protein-A and free β-human chorionic gonadotropin level, was higher in women of Afro-Caribbean and East-Asian racial origin than in Caucasians, and lower in smokers, but it was not significantly altered in pregnancies complicated by PE, SPB or SGA. The fetal cfDNA level was inversely related to maternal weight and uterine artery pulsatility index, and maternal cfDNA increased with maternal weight. Conclusions: The fetal and maternal cfDNA level in maternal plasma is affected by maternal and fetal characteristics, but it is not altered in pregnancy complications.

show abstract

Section: Discussionmentioning

confidence: 83%

Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes

Poon

Musci²,

Song³

et al. 2013

Fetal Diagn Ther

198

101

View full text Add to dashboard Cite

show abstract

“…Although the exact mechanism leading to the release of DNA in the circulation is not clear, apoptosis or some other form of cell death has been implicated (17,18). This hypothesis is supported by data indicating that circulating DNA shares many characteristics with apoptotic DNA fragments (19).…”

Section: Discussionmentioning

confidence: 99%

Antiphospholipid and Anti‐DNA Antibodies Are Not Associated with the Elevated Release of Circulatory Fetal DNA in Pregnancies Affected by Preeclampsia

Hristoskova

Holzgreve²,

Hahn³

2004

Hypertension in Pregnancy

View full text Add to dashboard Cite

show abstract

“…become a focus of greater interest, largely because of the discovery of cancer-specific DNA sequences in tumor patients and fetal genetic loci in the plasma of pregnant women (20,21 ). Increases in total cell-free DNA have been detected in a variety of conditions, with higher concentrations of cell-free DNA attributed to increased turnover, damage, or death of cells (22)(23)(24). The concentrations of cell-free DNA we measured in the plasma of healthy controls were in line with those previously reported, as were the higher concentrations in serum (25 ).…”

Section: Discussionmentioning

confidence: 99%

Increased Concentrations of Antibody-Bound Circulatory Cell-Free DNA in Rheumatoid Arthritis

et al. 2007

View full text Add to dashboard Cite

Background: Increased concentrations of cell-free DNA have been found in several disorders and have been interpreted as evidence of increased rates of cell death or turnover. Evidence from in vitro and animal experiments suggests that DNA may play a role in the pathogenesis of rheumatoid arthritis (RA). Methods: We measured cell-free DNA in plasma and serum from patients with RA and healthy controls by use of quantitative PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DNA. We used protein G Sepharose TM bead adsorption of plasma and elution to isolate antibody-bound DNA. Results: In paired plasma and serum samples of 16 healthy controls the median GAPDH copies were 4500 genome equivalents (GE)/mL plasma (range 319 -21 000) and in 26 RA patients 17 000 GE/mL plasma (2100 -2 375 000, P ‫؍‬ 0.0001). In the serum from normal controls the median GAPDH copies were 35 000 GE/mL (1700 -239 000) and from RA patients 222 000 GE/mL (21 000 -2 375 000, P ‫؍‬ 0.004). A median of 81% of the cell-free DNA in RA was associated with antibody compared with 9% in healthy controls (P ‫؍‬ 0.001). The concentrations of DNA did not vary with the type of therapy patients received.

show abstract

Quantitation of blood plasma DNA as an index of in vivo cytotoxicity

Cited by 14 publications

References 22 publications

Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes

Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes

Antiphospholipid and Anti‐DNA Antibodies Are Not Associated with the Elevated Release of Circulatory Fetal DNA in Pregnancies Affected by Preeclampsia

Increased Concentrations of Antibody-Bound Circulatory Cell-Free DNA in Rheumatoid Arthritis

Contact Info

Product

Resources

About